Sectors
SMMT
Summit Therapeutics Inc.
17.45
1 x 16.18
1 x 18.77
bid
ask
-
0.69
3.79%
10:13 AM
timesize
| Ytd | -0.21% | |
| 1y | -24.42% |
17.30
day range
17.95
13.83
52 week range
30.98
| Open | 17.78 | Prev Close | 18.14 | Low | 17.30 | High | 17.95 | Mkt Cap | 13.50B |
| Vol | 263.57K | Avg Vol | 3.33M | EPS | -1.59 | P/E | N/A | Forward P/E | -16.90 |
| Beta | -1.25 | Short Ratio | 7.57 | Inst. Own | 15.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 18.75 | 200-d Avg | 19.30 | 1yr Est | 30.18 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-04-30 | 2026-03 | 0 | N/A | 0.09 | 27.27% |
| 2026-02-23 | 2025-12 | 0 | N/A | -0.07 | -31.82% |
| 2025-10-20 | 2025-09 | 0 | N/A | -0.17 | -121.43% |
| 2025-08-11 | 2025-06 | 0 | N/A | -0.66 | -660.00% |
| 2025-05-01 | 2025-03 | 0 | N/A | 0.01 | 10.00% |
| 2025-02-24 | 2024-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-01 | Piper Sandler | Upgrade | Neutral | Neutral |
| 2026-04-08 | Stifel | Upgrade | Buy | Buy |
| 2026-03-16 | Jefferies | Downgrade | Buy | Hold |
| 2026-02-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-02-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-10-20 | ANAND BHASKAR | Officer | 159.75K | Stock Award(Grant) |
| 2025-10-20 | DUGGAN ROBERT WILLIAM | Chief Executive Officer | 0.00 | Stock Award(Grant) |
| 2024-09-10 | HUBER JEFFREY T | Director | 0.00 | Stock Award(Grant) |
| 2025-10-20 | SONI MANMEET SINGH | Chief Operating Officer | 3.07M | Stock Award(Grant) |
| 2025-10-20 | XIA YU | Director | 0.00 | Purchase |
| 2025-10-20 | ZANGANEH MAHKAM | Chief Executive Officer | 0.00 | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Baker Bros. Advisors, LP | 36.39M | 660.13M | 4.69% |
| 2025-12-30 | FMR, LLC | 13.36M | 242.37M | 1.72% |
| 2026-03-30 | Blackrock Inc. | 9.65M | 175.12M | 1.24% |
| 2025-12-30 | Price (T.Rowe) Associates Inc | 9.37M | 170.00M | 1.21% |
| 2025-12-30 | State Street Corporation | 6.64M | 120.38M | 0.86% |
| 2026-03-30 | Vanguard Capital Management LLC | 5.71M | 103.61M | 0.74% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | T. Rowe Price Health Sciences Fund, Inc. | 7.29M | 132.17M | 0.94% |
| 2026-04-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 5.44M | 98.68M | 0.70% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.53M | 64.01M | 0.45% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.54M | 46.03M | 0.33% |
| 2026-03-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.52M | 45.70M | 0.32% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.63M | 29.64M | 0.21% |
